Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Leukemia|April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trialN J Bahlis, A Corso, L-O Mugge, et al.
Leukemia|November 25, 2005
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapyS de Botton, M A Sanz, S Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia groupS de Botton, A Fawaz, S Chevret, et al.
Leukemia|November 27, 2004
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experienceL Ades, S Chevret, S De Botton, et al.
Bone Marrow Transplantation|October 12, 1999
Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow TransplantationG Gahrton, H Svensson, B Björkstrand, et al.
British Journal of Haematology|September 12, 1998
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized studyE Wattel, E Solary, B Hecquet, et al.
Advances in Experimental Medicine and Biology|September 29, 1999
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMSE Wattel, E Solary, B Hecquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2016
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaG Fouquet, B Pegourie, M Macro, et al.
Leukemia|July 30, 2013
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patientsB Hebraud, X Leleu, V Lauwers-Cances, et al.
Pageof 12